Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SB-318 in MPS I
NCT02702115Phase 2Terminated
- Sponsor
- Sangamo Therapeutics
- Start
- May 2017
- Primary completion
- Nov 2021
- Modality
- Gene Silencing, Zinc Finger Nucleases, AAV Vectors
- Countries
- 1
01
Overview
Phase 2, open-label trial of devafidugene civaparvovec in mucopolysaccharidosis type I (3 cohorts), sponsored by Sangamo Therapeutics. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events at 36 months. Started May 2017; status: terminated.
02
Drugs
devafidugene civaparvovec
03
Conditions
mucopolysaccharidosis type I
Beyond the preview
Go deeper on NCT02702115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02702115.